A Phase 2/3 interventional study of Sodium Zirconium Cyclosilicate (ZS) 5g and Sodium Zirconium Cyclosilicate (ZS) 10g in Hyperkalemia, sponsored by AstraZeneca. Completed at 25 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-20.
Sponsored by AstraZeneca · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia — 3 open to participants now, 4 under way, none of them phase 3. sodium zirconium cyclosilicate · Hyperkalemia.
Among the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, this one is the 17th largest by enrollment, is one of 4 that started in 2017, is the only one in phase 2/3, and was the 5th registered.
134 studies on the registry are indexed under Hyperkalemia; 26 are open to participants now.
Browse Hyperkalemia studies →3 of the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia are open now, in 2 countries. Recruiting first, the newest first:
AstraZeneca · Sites in India
Ages 18+
Leiden University Medical Center · Sites in Netherlands
Ages 18+
Qianfoshan Hospital
Ages 18–75
By country, each count listing its studies:
sodium zirconium cyclosilicate: first FDA approval 2018 (LOKELMA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 16 Hyperkalemia studies recruiting now, 11 (69%) set no upper age limit and 2 (13%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 13 · Phase 4 6
First in 2014; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 103 is above the median of 88 across 103 interventional studies indexed under Hyperkalemia.
Median enrollment 120 across the 27 interventional studies. Of the 22 that completed or were terminated, 18 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 27 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
39 studies in Hyperkalemia by AstraZeneca: 2 open now, 3 under way, 1 of them phase 3. Of 36 finished, 22 (61%) have results posted.
Among the 39 studies in Hyperkalemia by AstraZeneca, this one is the 18th largest by enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2017, is the only one in phase 2/3, and was the 10th registered.
AstraZeneca’s Hyperkalemia studies by the year they started, since 2011.
2 of the studies testing sodium zirconium cyclosilicate in Hyperkalemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06736184Qianfoshan HospitalThe Cardioprotective Effects of Improving Potassium Variability in Maintenance Hemodialysis Patients | 2026-12-31 |
| NCT07944378AstraZenecaA Study Evaluating the Safety and Effectiveness of Lokelma in Indian Patients With Hyperkalaemia | 2027-10-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, from their registry updates:
Among AstraZeneca’s 39 in Hyperkalemia:
This tab as a report to print or save as PDF → With an account.
To assess efficacy of 5 g three times daily (TID) and 10 g TID ZS versus placebo in Japanese patients with hyperkalemia (serum potassium [S-K] ≥ 5.1 mmol/L and ≤ 6.5 mmol/L).
Patients not receiving any therapy for hyperkalemia and with 2 consecutive i-STAT potassium values of ≥ 5.1 mmol/L and ≤ 6.5 mmol/L will be enrolled and randomized 1:1:1 to receive ZS 5 g, ZS 10 g, or placebo TID for 48 hours.
Throughout the study most potassium values will be measured at fasting before taking study drug. Nothing should be taken by mouth except water, coffee or tea, with or without milk and/or sugar, and essential medications, prior to the blood collection for a minimum of 8 hours. Potassium level should be determined by both i-STAT and the Central Laboratory on all occasions. Treatment decisions (eg, stopping rules) will be made based on i-STAT potassium values, as these provide clinical sites with a real-time measurement. Statistical analyses on the study data will in principle be based on S-K values as measured by the central laboratory.
Safety and tolerability will be assessed on an ongoing basis. Standard study assessments including blood potassium, clinical chemistry (including calcium, magnesium, sodium, phosphate, creatinine, bicarbonate, and blood urea nitrogen [BUN]) and hematology parameters, urinalysis, vital signs, physical examinations, and electrocardiograms (ECGs) will be assessed during the study at the time points specified in the assessments schedule. All women of childbearing potential will have a urine pregnancy test prior to enrollment and at their End of Study (EOS) visit.
Stopping rules will be implemented to ensure subjects discontinue the study treatment and receive alternative therapy in case of significant hyperkalemia, hypokalemia, or significant cardiac arrhythmias.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Cause or symptoms of pseudohyperkalemia, such as
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Suspension administered 5g orally three times daily for 48 hours.
Drug: Sodium Zirconium Cyclosilicate (ZS) 5g
Suspension administered 10g orally three times daily for 48 hours.
Drug: Sodium Zirconium Cyclosilicate (ZS) 10g
Placebo suspension administered orally placebo three times daily for 48 hours.
Drug: Placebo
Suspension administered 5g orally three times daily for 48 hours.
Suspension administered 10g orally three times daily for 48 hours.
Placebo suspension administered orally placebo three times daily for 48 hours.
Exponential Rate of Change in Serum Potassium (S-K) Values During the Initial 48 Hours of Study Drug Treatment
Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or \<4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed at the Central Laboratory. Natural logarithm of S-K from 0 to 48 hours post dose are modelled by the random coefficients model including fixed effects of intercept, time, time x treatment and patient-level random effects for time and intercept. Exponential rate of change refers to the slope estimate from the random coefficients model.
Time frame: From 0 to 48 hours.
Percentage of Patients Who Achieved Normokalaemia at 48 Hours
The percentage of patients who achieved normokalaemia (normalisation of S-K values to between 3.5 mmol/L and 5.0 mmol/L, inclusive) at 48 hours after start of dosing was determined. Patients with missing S-K values at 48 hours were regarded as not normokalaemic.
Time frame: At 48 hours.
Exponential Rate of Change in S-K Values During the Initial 24 Hours of Study Drug Treatment
Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or \<4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed at the Central Laboratory. Natural logarithm of S-K from 0 to 24 hours post dose are modelled by the random coefficients model including fixed effects of intercept, time, time x treatment and patient-level random effects for time and intercept. Exponential rate of change refers to the slope estimate from the random coefficients model.
Time frame: From 0 to 24 hours.
Percentage of Patients Who Achieved Normokalaemia at 24 Hours
The percentage of patients who achieved normokalaemia (normalisation of S-K values to between 3.5 mmol/L and 5.0 mmol/L, inclusive) at 24 hours after start of dosing was determined. Patients with missing S-K values at 24 hours were regarded as not normokalaemic.
Time frame: At 24 hours.
Percentage of Patients Who Achieved Normokalaemia at Each Scheduled Potassium Assessment Time Point
The percentage of patients who achieved normokalaemia (normalisation of S-K values to between 3.5 mmol/L and 5.0 mmol/L, inclusive) at each each scheduled potassium assessment time point after the start of dosing was determined. Patients with missing S-K values were regarded as not normokalaemic.
Time frame: From baseline to end of study (9 days).
Mean Change From Baseline in S-K Values at All Measured Time Intervals
Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or \<4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed locally using i-STAT devices, and at the Central Laboratory. S-K values measured at each time point and end of study visit were recorded and mean change from baseline is displayed.
Time frame: From baseline to end of study (9 days).
Mean Percent Change From Baseline in S-K Values at All Measured Time Intervals
Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or \<4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed locally using i-STAT devices, and at the Central Laboratory. S-K values measured at each time point and end of study visit were recorded and mean percent change from baseline is displayed.
Time frame: From baseline to end of study (9 days).
Time to Normalisation in S-K Values
The distribution of time to normalisation of S-K values (defined as S-K values between 3.5 mmol/L and 5.0 mmol/L, inclusive) was measured. A patient who reached at least one S-K within normal range was counted as an event regardless of S-K value after that time point. Patients who did not achieve normokalaemia within 48 hours were censored.
Time frame: From 0 to 48 hours.
Time to a Decrease in S-K Levels of 0.5 mmol/L
The median time (hours) for S-K values to decrease by 0.5 mmol/L was measured.
Time frame: From 0 to 48 hours.
Patients not receiving any therapy for hyperkalaemia and with 2 consecutive potassium values of ≥ 5.1 millimoles/litre (mmol/L) and ≤ 6.5 mmol/L (as measured by i-STAT, a portable blood analyser) were enrolled into 24 study sites in Japan from June 2017 to February 2018.
| Milestone | ZS 5 g TID | ZS 10 g TID | Placebo TID |
|---|---|---|---|
| Started | 34 | 36 | 33 |
| Completed | 34 | 36 | 31 |
| Not completed | 0 | 0 | 2 |
| Withdrew: Study-specific withdrawal criteria | 0 | 0 | 2 |
Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or \<4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed at the Central Laboratory. Natural logarithm of S-K from 0 to 48 hours post dose are modelled by the random coefficients model including fixed effects of intercept, time, time x treatment and patient-level random effects for time and intercept. Exponential rate of change refers to the slope estimate from the random coefficients model.
| log (mmol/L) / hour | ZS 5 g TID | ZS 10 g TID | Placebo TID |
|---|---|---|---|
| Exponential Rate of Change in Serum Potassium (S-K) Values During the Initial 48 Hours of Study Drug Treatment | -0.00273 ± 0.000276 | -0.00508 ± 0.000269 | -0.00012 ± 0.000288 |
The percentage of patients who achieved normokalaemia (normalisation of S-K values to between 3.5 mmol/L and 5.0 mmol/L, inclusive) at 48 hours after start of dosing was determined. Patients with missing S-K values at 48 hours were regarded as not normokalaemic.
| Percentage of Patients | ZS 5 g TID | ZS 10g TID | Placebo TID |
|---|---|---|---|
| Percentage of Patients Who Achieved Normokalaemia at 48 Hours | 85.3 | 91.7 | 15.2 |
Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or \<4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed at the Central Laboratory. Natural logarithm of S-K from 0 to 24 hours post dose are modelled by the random coefficients model including fixed effects of intercept, time, time x treatment and patient-level random effects for time and intercept. Exponential rate of change refers to the slope estimate from the random coefficients model.
| log (mmol/L) / hour | ZS 5 g TID | ZS 10 g TID | Placebo TID |
|---|---|---|---|
| Exponential Rate of Change in S-K Values During the Initial 24 Hours of Study Drug Treatment | -0.00234 ± 0.000468 | -0.00403 ± 0.000457 | -0.00002 ± 0.000489 |
The percentage of patients who achieved normokalaemia (normalisation of S-K values to between 3.5 mmol/L and 5.0 mmol/L, inclusive) at 24 hours after start of dosing was determined. Patients with missing S-K values at 24 hours were regarded as not normokalaemic.
| Percentage of Patients | ZS 5 g TID | ZS 10g TID | Placebo TID |
|---|---|---|---|
| Percentage of Patients Who Achieved Normokalaemia at 24 Hours | 35.3 | 83.3 | 27.3 |
The percentage of patients who achieved normokalaemia (normalisation of S-K values to between 3.5 mmol/L and 5.0 mmol/L, inclusive) at each each scheduled potassium assessment time point after the start of dosing was determined. Patients with missing S-K values were regarded as not normokalaemic.
| Percentage of Patients | ZS 5 g TID | ZS 10g TID | Placebo TID |
|---|---|---|---|
| Baseline | 2.9 | 5.6 | 0.0 |
| 1 hour after first dose | 29.4 | 47.2 | 21.2 |
| 2 hours after first dose | 41.2 | 58.3 | 42.4 |
| 4 hours after first dose | 44.1 | 63.9 | 42.4 |
| 24 hours after first dose | 35.3 | 83.3 | 27.3 |
| 25 hours after first dose | 73.5 | 97.2 | 18.2 |
| 28 hours after first dose | 67.6 | 97.2 | 36.4 |
| 48 hours after first dose | 85.3 | 91.7 | 15.2 |
| End of study (Last dose + 7 days) | 55.9 | 61.1 | 27.3 |
Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or \<4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed locally using i-STAT devices, and at the Central Laboratory. S-K values measured at each time point and end of study visit were recorded and mean change from baseline is displayed.
| mmol/L | ZS 5 g TID | ZS 10g TID | Placebo TID |
|---|---|---|---|
| 1 hour after first dose | -0.20 ± 0.34 | -0.37 ± 0.35 | -0.13 ± 0.32 |
| 2 hours after first dose | -0.41 ± 0.28 | -0.50 ± 0.40 | -0.33 ± 0.30 |
| 4 hours after first dose | -0.40 ± 0.32 | -0.53 ± 0.36 | -0.43 ± 0.31 |
| 24 hours after first dose | -0.51 ± 0.30 | -0.69 ± 0.38 | -0.22 ± 0.35 |
| 25 hours after first dose | -0.74 ± 0.31 | -1.00 ± 0.45 | -0.27 ± 0.31 |
| 28 hours after first dose | -0.72 ± 0.35 | -1.12 ± 0.39 | -0.41 ± 0.43 |
| 48 hours after first dose | -0.83 ± 0.31 | -1.30 ± 0.48 | -0.24 ± 0.34 |
| End of study (Last dose + 7 days) | -0.56 ± 0.38 | -0.66 ± 0.52 | -0.20 ± 0.59 |
Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or \<4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed locally using i-STAT devices, and at the Central Laboratory. S-K values measured at each time point and end of study visit were recorded and mean percent change from baseline is displayed.
| Percent change | ZS 5 g TID | ZS 10g TID | Placebo TID |
|---|---|---|---|
| 1 hour after first dose | -3.61 ± 6.28 | -6.72 ± 6.29 | -2.32 ± 5.60 |
| 2 hours after first dose | -7.46 ± 5.04 | -9.07 ± 6.88 | -6.06 ± 5.40 |
| 4 hours after first dose | -7.08 ± 5.65 | -9.70 ± 6.53 | -7.77 ± 5.62 |
| 24 hours after first dose | -8.98 ± 5.33 | -12.51 ± 6.30 | -3.81 ± 6.24 |
| 25 hours after first dose | -13.20 ± 5.42 | -18.06 ± 7.05 | -4.77 ± 5.66 |
| 28 hours after first dose | -12.90 ± 6.10 | -20.47 ± 6.38 | -7.21 ± 7.61 |
| 48 hours after first dose | -14.81 ± 5.08 | -23.64 ± 8.27 | -4.06 ± 5.93 |
| End of study (Last dose + 7 days) | -9.85 ± 6.51 | -11.89 ± 9.07 | -3.15 ± 9.99 |
The distribution of time to normalisation of S-K values (defined as S-K values between 3.5 mmol/L and 5.0 mmol/L, inclusive) was measured. A patient who reached at least one S-K within normal range was counted as an event regardless of S-K value after that time point. Patients who did not achieve normokalaemia within 48 hours were censored.
| Hours | ZS 5g TID | ZS 10g TID | Placebo TID |
|---|---|---|---|
| Time to Normalisation in S-K Values | 3.883 (1.767 to 23.083) | 1.758 (1.000 to 3.967) | 3.867 (1.917 to NA) |
The median time (hours) for S-K values to decrease by 0.5 mmol/L was measured.
| Hours | ZS 5g TID | ZS 10g TID | Placebo TID |
|---|---|---|---|
| Time to a Decrease in S-K Levels of 0.5 mmol/L | 3.883 (1.933 to 19.767) | 2.892 (1.083 to 4.100) | 4.050 (1.983 to 23.667) |
Collected over Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ZS 5 g TID | 0/34 (0%) | 0/34 (0%) | 4/34 (11.8%) |
| ZS 10 g TID | 0/36 (0%) | 0/36 (0%) | 5/36 (13.9%) |
| Placebo TID | 0/33 (0%) | 0/33 (0%) | 1/33 (3%) |
| Event | ZS 5 g TID | ZS 10 g TID | Placebo TID |
|---|---|---|---|
| Respiratory tract infectionInfections and infestations | 0/34 | 0/36 | 1/33 |
| Viral upper respiratory tract infectionInfections and infestations | 1/34 | 0/36 | 0/33 |
| Nephrogenic anaemiaBlood and lymphatic system disorders | 1/34 | 0/36 | 0/33 |
| ConstipationGastrointestinal disorders | 1/34 | 0/36 | 0/33 |
| ThirstGeneral disorders | 1/34 | 0/36 | 0/33 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/34 | 1/36 | 0/33 |
| Tension headacheNervous system disorders | 0/34 | 1/36 | 0/33 |
| TremorNervous system disorders | 0/34 | 1/36 | 0/33 |
| Ventricular extrasystolesCardiac disorders | 0/34 | 1/36 | 0/33 |
| ErythemaSkin and subcutaneous tissue disorders | 0/34 | 1/36 | 0/33 |
The full analysis set included all patients randomised in the study.
| Age, Continuous(Years) | ZS 5 g TID | ZS 10 g TID | Placebo TID | Total |
|---|---|---|---|---|
| Mean | 72.4 ± 7.9 | 71.1 ± 7.6 | 76.1 ± 6.8 | 73.2 ± 7.7 |
| Age, Customized(Participants) | ZS 5 g TID | ZS 10 g TID | Placebo TID | Total |
|---|---|---|---|---|
| <55 years | 0 | 1 | 0 | 1 |
| 55 to 64 years | 7 | 4 | 1 | 12 |
| ≥65 years | 27 | 31 | 32 | 90 |
| Sex: Female, Male(Participants) | ZS 5 g TID | ZS 10 g TID | Placebo TID | Total |
|---|---|---|---|---|
| Female | 8 | 8 | 10 | 26 |
| Male | 26 | 28 | 23 | 77 |
| Ethnicity (NIH/OMB)(Participants) | ZS 5 g TID | ZS 10 g TID | Placebo TID | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 34 | 36 | 33 | 103 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | ZS 5 g TID | ZS 10 g TID | Placebo TID | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 34 | 36 | 33 | 103 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2017 to primary completion in Feb 2018, 8 months.
Results were first posted in May 2019, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium zirconium cyclosilicate